lyophilized powder raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-12-14. Anything still debated is marked as such rather than presented as settled.
The compound has been investigated as an adjunct in chronic viral hepatitis and as a vaccine adjuvant, with results that vary by study design and population. Regulators in some countries have approved a synthetic form for specific indications, while other agencies have not. Whether the peptide produces consistent clinical benefit across diverse patient groups is still an open question, and many trials have been small. Its status is therefore best described as investigational in many contexts and established only narrowly.
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
| Property | Value | Notes |
|---|---|---|
| Residue count | 28 amino acids | Acetyl group on the first residue |
| Approximate molecular mass | 3108 daltons | Calculated from the consensus sequence |
| Origin | Cleavage product of prothymosin alpha | Not encoded as a separate gene product |
| Primary research focus | Immune modulation | Studied in viral hepatitis and as a vaccine adjuvant |
| Common synonyms | Thymalfasin, Tα1, thymosin alpha 1 | Thymalfasin is the assigned nonproprietary name |
Identity and purity are assessed with a small set of standard peptide methods. Reversed-phase high-performance liquid chromatography separates the main peak from truncated or oxidized species, and its area percentage is the usual purity measure. Mass spectrometry confirms the observed molecular mass against the expected value, while amino acid analysis or peptide mapping checks composition and sequence. Specifications for research-grade material are often stated as 95 percent or higher, though the exact limit depends on the supplier and the intended use.
Laboratory supplies of the peptide usually arrive as a lyophilized powder in sealed vials. The powder is hygroscopic, so a vial should be allowed to reach room temperature before it is opened to prevent condensation on the contents. Weighing and transfer are best performed in a low-humidity environment with clean tools. Once dissolved, the solution should be mixed gently rather than vortexed, because foaming and shear can reduce recovery of the peptide.
市售的胸腺素α1通常以冻干粉形式提供，溶解后用于注射。其氨基酸组成包括多个酸性残基，因此在中性pH下带负电荷。该肽可溶于水和生理盐水，但在有机溶剂中溶解度有限。储存条件通常为冻干状态下负20摄氏度，溶解后需冷藏并避免反复冻融。常见的同义词包括胸腺肽α1、thymalfasin和Tα1。
胸腺素α1（thymosin alpha 1，Tα1）是一种由28个氨基酸组成的酸性肽，N端被乙酰化，分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离，属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守，提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置，并非表示亚型编号。它既存在于胸腺，也存在于脾脏和淋巴结等免疫组织。
20世纪70年代，研究者从胸腺提取物中纯化出多种小肽，Tα1是其中被较早表征的一种。最初的制备依赖组织匀浆和层析步骤，产量低且成分复杂。随着固相肽合成技术成熟，实验室和工业界能够生产与天然序列一致的合成版本。合成肽的纯度可达95%以上，并可通过反相高效液相色谱和质谱进行鉴定。这一转变使研究不再依赖动物胸腺来源。
=== Chemical-pharmaceutical industry and laboratories === Acetonitrile is used as a solvent, particularly in the pharmaceutical industry. According to a market analysis, approximately 180,000 tons of acetonitrile were produced worldwide in 2022, of which around 70% was consumed by the pharmaceutical sector. It is also one of the most important solvents for analyses performed by high-performance liquid chromatography. The thermal decomposition of azobisisobutyronitrile (AIBN) and related compounds (e.g., azobis(cyclohexanecarbonitrile)) generates relatively stable radicals; accordingly, these compounds are used as radical initiators in radical reactions, particularly polymerizations. The quinone DDQ, which contains two nitrile groups, is a widely used oxidizing agent, including in pharmaceutical synthesis. Nitrile groups can be incorporated into biomolecules as probes for infrared spectroscopic investigations. Some nitriles serve as starting materials for the synthesis of pharmaceuticals. Ketoprofen is an anti-inflammatory agent approved in some EU countries; propionitrile is used in its industrial synthesis.
Experiments on its genotoxicity at high doses are inconsistent. Its oxidized form TBBQ may be responsible for some toxic effects. There exists a wide margin of safety between food-additive doses and doses used in studies. There have been reports of vision disturbances in individuals exposed to this chemical.
=== Reduction reactions === Under alkaline conditions, hydrogen peroxide is a reductant. When H2O2 acts as a reducing agent, oxygen gas is also produced. For example, hydrogen peroxide will reduce sodium hypochlorite and potassium permanganate, which is a convenient method for preparing oxygen in the laboratory:
AdventHealth Polk South, Inc. (doing business as AdventHealth Lake Wales) is a non-profit hospital campus in Lake Wales, Florida, United States owned by AdventHealth. The medical facility is a tertiary and primary stroke center that has multiple specialties. It was purchased from Community Health Systems in May 2019.
The Wound Man is a surgical diagram which first appeared in European medical manuscripts of the fourteenth and fifteenth centuries. The illustration acted as an annotated table of contents to guide the reader through various injuries and diseases whose related cures could be found on the text's nearby pages. The image first appeared in a printed book in 1491 when it was included in the Venetian Fasciculus medicinae, likely Europe's first printed medical miscellany. Thereafter it circulated widely in printed books until well into the seventeenth century. The Wound Man has since become a recognisable figure in popular culture.
Sources: en.wikipedia.org
=== Research === Although bilberries have been used in traditional medicine, there are no proven health benefits or antidisease effects from consuming them. One review of low-quality clinical research concluded there was no evidence that consuming bilberries improves night vision.
One pathway involves alcohol dehydrogenase, particularly the IB (class I), beta polypeptide (ADH1B, EC 1.1.1.1) enzyme. The reaction uses NAD+ to convert the ethanol into acetaldehyde (a toxic carcinogen). The enzyme acetaldehyde dehydrogenase (aldehyde dehydrogenase 2 family ALDH2, EC 1.2.1.3) then converts the acetaldehyde into the non-toxic acetate ion (commonly found in acetic acid or vinegar). This ion is in turn is broken down into carbon dioxide and water. Specifically, acetate combines with coenzyme A (acetyl-CoA synthetase) to form acetyl-CoA, via the enzymes acyl-CoA synthetase short-chain family member 2 ACSS2 (EC 6.2.1.1) and acetyl-CoA synthase 2 (ACSS1). acetyl-CoA then participates in the citric acid cycle. At even low physiological concentrations, ethanol completely saturates alcohol dehydrogenase. This is because ethanol has high affinity for the enzyme and very high concentrations of ethanol occur when it is used as a recreational substance. The microsomal ethanol-oxidizing system (MEOS), specifically mediated by the cytochrome P450 enzyme CYP2E1, is another major route of ethanol metabolism. CYP2E1 is predominantly active at higher concentrations. Repeated or chronic use of ethanol increases the activity of CYP2E1. The activity of ADH and CYP2E1 alone does not appear sufficient to fully explain the increase in ethanol metabolism rate. There may be one or more additional pathways that metabolize as much as 25 to 35% of ethanol at typical concentrations. A small amount of ethanol undergoes conjugation to form ethyl glucuronide and ethyl sulfate.
== Further reading == Timeline of Materials Science Archived 2011-07-27 at the Wayback Machine at The Minerals, Metals & Materials Society (TMS) – accessed March 2007 Burns, G.; Glazer, A.M. (1990). Space Groups for Scientists and Engineers (2nd ed.). Boston: Academic Press, Inc. ISBN 978-0-12-145761-7. Cullity, B.D. (1978). Elements of X-Ray Diffraction (2nd ed.). Reading, Massachusetts: Addison-Wesley Publishing Company. ISBN 978-0-534-55396-8. Giacovazzo, C; Monaco HL; Viterbo D; Scordari F; Gilli G; Zanotti G; Catti M (1992). Fundamentals of Crystallography. Oxford: Oxford University Press. ISBN 978-0-19-855578-0. Green, D.J.; Hannink, R.; Swain, M.V. (1989). Transformation Toughening of Ceramics. Boca Raton: CRC Press. ISBN 978-0-8493-6594-2. Lovesey, S. W. (1984). Theory of Neutron Scattering from Condensed Matter; Volume 1: Neutron Scattering. Oxford: Clarendon Press. ISBN 978-0-19-852015-3. Lovesey, S. W. (1984). Theory of Neutron Scattering from Condensed Matter; Volume 2: Condensed Matter. Oxford: Clarendon Press. ISBN 978-0-19-852017-7. O'Keeffe, M.; Hyde, B.G. (1996). "Crystal Structures; I. Patterns and Symmetry". Zeitschrift für Kristallographie – Crystalline Materials. 212 (12). Washington, DC: Mineralogical Society of America, Monograph Series: 899. Bibcode:1997ZK....212..899K. doi:10.1524/zkri.1997.212.12.899. ISBN 978-0-939950-40-9.{{cite journal}}: CS1 maint: periodical has ISBN (link) Squires, G.L. (1996). Introduction to the Theory of Thermal Neutron Scattering (2nd ed.). Mineola, New York: Dover Publications Inc. ISBN 978-0-486-69447-4.
Michael Laposata is an American pathologist, fatty acid biochemist and specialist in blood coagulation. He was chair of the Department of Pathology at the University of Texas Medical Branch (UTMB) in Galveston and previously directed clinical laboratories at Massachusetts General Hospital and Vanderbilt University.[1][2] He is known for developing diagnostic management teams to recommend the correct tests and provide expert driven, patient specific interpretations of test results. He is also well known for his work on bleeding disorders misdiagnosed as child abuse, and as a plaintiff in the 2024 lawsuit that overturned the U.S. Food and Drug Administration's rule on laboratory developed tests.[1][3][4] In 2026 he founded ExpertDx, Inc.
Extensive research has been conducted to determine equivalence ratios comparing the relative potency of opioids. Given a dose of an opioid, an equianalgesic table is used to find the equivalent dosage of another. Such tables are used in opioid rotation practices, and to describe an opioid by comparison to morphine, the reference opioid. Equianalgesic tables typically list drug half-lives, and sometimes equianalgesic doses of the same drug by means of administration, such as morphine: oral and intravenous.
Sources: en.wikipedia.org
It is usually classified as an immunomodulatory peptide rather than a classical hormone. It derives from the larger protein prothymosin alpha and acts mainly on immune cells. The thymosin label covers a group of distinct peptides, so the naming can be misleading.
The two share a family name but have different sequences, sizes, and functions. Thymosin beta-4 is a 43-residue peptide associated with actin binding and cell migration. Thymosin alpha-1 is a 28-residue peptide linked mainly to immune signaling.
Thymalfasin is the assigned international nonproprietary name for the synthetic 28-residue peptide. Thymosin alpha-1 is the descriptive research name for the same molecule. Which term appears depends on the context and the regulatory document.
Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.